Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.66) earnings per share (EPS) for the quarter, Zacks reports.
Eloxx Pharmaceuticals Price Performance
Shares of NASDAQ ELOX traded up $0.16 during midday trading on Thursday, reaching $18.42. 16,195 shares of the stock were exchanged, compared to its average volume of 56,748. The stock has a market capitalization of $12.71 million, a P/E ratio of -1.20 and a beta of -1,864.08. Eloxx Pharmaceuticals has a 52-week low of $8.20 and a 52-week high of $19.96. The stock’s 50 day simple moving average is $15.28.
Analyst Ratings Changes
Several brokerages have recently issued reports on ELOX. Lifesci Capital began coverage on Eloxx Pharmaceuticals in a research note on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 price objective for the company. Wall Street Zen raised Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st. Finally, Guggenheim began coverage on shares of Eloxx Pharmaceuticals in a research report on Monday, July 20th. They set a “buy” rating and a $43.00 target price on the stock. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Eloxx Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $41.50.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.
Read More
- Five stocks we like better than Eloxx Pharmaceuticals
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
- Lumentum Just Delivered the AI Growth Investors Wanted
- Ryman Checks Into a $1.38B Hospitality Upgrade
- Axos Financial Keeps Proving the Digital Banking Model Works
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
